AGP Picks
View all

Boston Technology Review: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Boston Technology Review.

Press releases published on August 3, 2026

BridgeBio to Report Second Quarter 2026 Financial Results and Commercial Updates on August 10, 2026 at 4:30 pm ET
ARS Pharmaceuticals Announces Conference Call and Webcast on August 13 Outlining its Updated Strategic Priorities and Reporting Second Quarter 2026 Financial Results
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crescent Biopharma Announces Grants of Inducement Awards
Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom
Zevra Therapeutics Announces Publication of Four-Year Real-World Data from U.S. Early Access Program Evaluating MIPLYFFA® (arimoclomol) in Niemann-Pick Disease Type C (NPC)
OwlTing Group (NASDAQ: OWLS) Reports OwlPay Harbor July Payment Volume Increased 107.6% Month Over Month
Veritasium Goes Behind the Scenes at Kraig Biocraft Laboratories to Explore the Future of Commercial Spider Silk
PCI SSC Europe Community Meeting feiert 20-jähriges Jubiläum und kehrt nach Edinburgh zurück
Le PCI SSC Europe Community Meeting revient à Édimbourg pour célébrer son 20e anniversaire
OutSolve Earns Two-Star Certification from The DaVinci Awards®
Lantronix CEO and CFO to Participate in Canaccord Genuity and Needham Conferences
Blancco Leaders to Speak at ITAD Summit on Building Smarter, More Efficient IT Asset Processing Operations
Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health
VisionWave Files International Trademark Application for STRATUM™ AI Platform
Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results
EVA LIVE INC. ANNOUNCES FORMATION OF EVA DEFENSE ADVISORY BOARD, APPOINTS GENERAL ROBERT BROOKS BROWN (R) AND ROSS MANDEL
Adlai Nortye Announces Clinical Trial Notification Submission and HREC Approval for the Phase I Clinical Trial of Pan-RAS(ON) Inhibitor ADC AN4035 in Australia
Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights
TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Boston Technology Review

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.